KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Free Cash Flow (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Free Cash Flow data on record, last reported at -$48.9 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 9.59% year-over-year to -$48.9 million; the TTM value through Sep 2025 reached -$190.4 million, down 7.05%, while the annual FY2024 figure was -$177.2 million, 8.42% up from the prior year.
  • Free Cash Flow reached -$48.9 million in Q3 2025 per NKTR's latest filing, down from -$45.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$37.9 million in Q2 2024 and bottomed at -$157.4 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$65.9 million, with a median of -$51.7 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: tumbled 90.66% in 2021, then soared 63.02% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$157.4 million in 2021, then skyrocketed by 63.02% to -$58.2 million in 2022, then grew by 18.78% to -$47.3 million in 2023, then increased by 1.35% to -$46.6 million in 2024, then decreased by 4.78% to -$48.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$48.9 million in Q3 2025, -$45.8 million in Q2 2025, and -$49.1 million in Q1 2025.